Treatment of acute duodenal ulcers with famotidine and its comparison with other H2 blockers.
Famotidine, a new H2 antagonist in a dose of 40 mg qhs was tried in a clinical trial for the treatment of duodenal ulcer in 25 patients and compared with other H2 antagonists. Cimetidine 800 mg qhs and Ranitidine 300 mg qhs were used in a similar number of randomised patients. Patients were evaluated clinically, biochemically and endoscopically. At the end of eight weeks, the healing rate with Famotidine was 96%. Cimetidine was 92% and Ranitidine 96%. No significant side effects were noted with any of these drugs. In conclusion, Famotidine (40 mg qhs) is an effective and generally well-tolerated drug in the treatment of acute duodenal ulcer.
Akhtar
M A
MA
Department of Medicine, Combined Military Hospital, Rawalpindi.
Rashid
P
P
Khan
M A
MA
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D004381:Duodenal Ulcer / Q000188:drug therapy*; D015738:Famotidine / Q000627:therapeutic use*; D005260:Female; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged
D006635:Histamine H2 Antagonists; D015738:Famotidine